Combination

X-energy and Ares Acquisition Corporation Mutually Agree to Terminate Business Combination Agreement

Retrieved on: 
Tuesday, October 31, 2023
Finance, Alternative Energy, Energy, Professional Services, Nuclear, Transfer, Combination, U.S. Department of Defense Strategy for Operating in Cyberspace, NYSE, New York Stock Exchange, Accounting, ARES, Energy Northwest, Wind, Acquisition, Final, Entrepreneurship, Electric Bond and Share Company v. Securities and Exchange Commission, Texas Gulf Coast, Redemption, Finance Secretary (India), Growth, Trust, Partner, United States Department of Energy, Dow, Interest on Lawyer Trust Accounts, Texas Gulf Coast Regional Airport, AAC, Defense, Cryptocurrency, Management, Security (finance), Article

X-Energy Reactor Company, LLC (“X-energy”), a leading developer of advanced small modular nuclear reactors and fuel technology for clean energy generation, and Ares Acquisition Corporation (NYSE: AAC) (“AAC”), a publicly-traded special purpose acquisition company, announced today that they have mutually agreed to terminate their previously announced business combination agreement (the “Business Combination Agreement”), effective immediately.

Key Points: 
  • X-Energy Reactor Company, LLC (“X-energy”), a leading developer of advanced small modular nuclear reactors and fuel technology for clean energy generation, and Ares Acquisition Corporation (NYSE: AAC) (“AAC”), a publicly-traded special purpose acquisition company, announced today that they have mutually agreed to terminate their previously announced business combination agreement (the “Business Combination Agreement”), effective immediately.
  • Neither party will be required to pay the other a termination fee as a result of the mutual decision to terminate the business combination agreement.
  • In view of the termination of the Business Combination Agreement, AAC determined that it will not be able to consummate an initial business combination within the time period required by its amended and restated memorandum and articles of association (as amended, the “Articles”).
  • As of November 6, 2023, AAC will cease all operations except those required to wind up AAC’s business.

Syntax and Beyond Technologies Complete Acquisition Deal, Officially Join Forces

Retrieved on: 
Thursday, November 2, 2023
Internet of things, Combination, Partner (business rank), Local, Organization, Acquisition, Specialization, Public sector, Ecosystem, Partnership, SAP, Natural Resources, Consultant, Management, Syntax

MONTRÉAL, Nov. 2, 2023 /PRNewswire/ -- Syntax Systems, a leading global technology solutions and services provider for cloud application implementation and management, and Montréal-based Beyond Technologies today announced the successful completion of the acquisition transaction. The deal, which was announced October 3, 2023, brings Beyond a professional services firm specializing in SAP® solution integration and business performance optimization into the Syntax family.

Key Points: 
  • MONTRÉAL, Nov. 2, 2023 /PRNewswire/ -- Syntax Systems , a leading global technology solutions and services provider for cloud application implementation and management, and Montréal-based Beyond Technologies today announced the successful completion of the acquisition transaction.
  • "Bringing the Syntax and Beyond teams together is directly aligned to our strength in delivering industry-first capabilities.
  • In June 2021, Syntax acquired Illumiti, a Syntax Company, an integration and management consultancy firm.
  • "Syntax's acquisition of Beyond Technologies represents the continued commitment to client success, ecosystem partnership, good corporate citizenship and being an employer of choice for technology talent.

Syntax and Beyond Technologies Complete Acquisition Deal, Officially Join Forces

Retrieved on: 
Thursday, November 2, 2023
Internet of things, Combination, Partner (business rank), Local, Organization, Acquisition, Specialization, Public sector, Ecosystem, Partnership, SAP, Natural Resources, Consultant, Management, Syntax

MONTRÉAL, Nov. 2, 2023 /PRNewswire/ -- Syntax Systems, a leading global technology solutions and services provider for cloud application implementation and management, and Montréal-based Beyond Technologies today announced the successful completion of the acquisition transaction. The deal, which was announced October 3, 2023, brings Beyond a professional services firm specializing in SAP® solution integration and business performance optimization into the Syntax family.

Key Points: 
  • MONTRÉAL, Nov. 2, 2023 /PRNewswire/ -- Syntax Systems , a leading global technology solutions and services provider for cloud application implementation and management, and Montréal-based Beyond Technologies today announced the successful completion of the acquisition transaction.
  • "Bringing the Syntax and Beyond teams together is directly aligned to our strength in delivering industry-first capabilities.
  • In June 2021, Syntax acquired Illumiti, a Syntax Company, an integration and management consultancy firm.
  • "Syntax's acquisition of Beyond Technologies represents the continued commitment to client success, ecosystem partnership, good corporate citizenship and being an employer of choice for technology talent.

Two Day Online Development of Combination Pharma Products Training Course: Focus on Critical Interactions - Navigating GMP and Quality in Pharma (February 12-13, 2024) - ResearchAndMarkets.com

Retrieved on: 
Friday, October 27, 2023
Training, Education, Combination, Good manufacturing practice, GMP, European, CTD, Research, R, Common Technical Document, Plasma protein binding, Medical device, EU

The "Development of Combination Products: Critical Interactions Training Course" conference has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Development of Combination Products: Critical Interactions Training Course" conference has been added to ResearchAndMarkets.com's offering.
  • This program provides valuable insights into crafting an effective regulatory strategy while addressing crucial aspects of Good Manufacturing Practices (GMP) and quality processes.
  • Our interactive seminar serves as a guide to understanding both the European Union (EU) and US approaches to handling drug/device and device/drug combination products.
  • Furthermore, this seminar will emphasize the interconnectedness of quality, regulatory affairs, research and development (R&D), and production functions.

Foundation Medicine Announces Participation in National Cancer Institute’s ComboMATCH Initiative to Connect Patients with New Anti-Cancer Drug Combinations

Retrieved on: 
Thursday, October 26, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Patient, Combination, NCI, Foundation Medicine, MD, Doctor of Philosophy, National Cancer Institute, Alliance for Clinical Trials in Oncology, Partnership, Cancer, Drug combination, Bangladesh Technical Education Board, Pharmaceutical industry, Nursing, Medical imaging

Foundation Medicine, Inc., today announced its participation in the National Cancer Institute’s (NCI) Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH) initiative to test new therapy combinations in select groups of adults and children with cancer.

Key Points: 
  • Foundation Medicine, Inc., today announced its participation in the National Cancer Institute’s (NCI) Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH) initiative to test new therapy combinations in select groups of adults and children with cancer.
  • Foundation Medicine is one of nearly 40 participating Designated Laboratories, meaning that oncologists at participating ComboMATCH clinical sites may utilize their patients' FoundationOne®CDx commercial testing results to help determine their eligibility for ComboMATCH treatment trials.
  • ComboMATCH tests whether therapy selected in this manner to treat cancer may provide better patient outcomes than the current standard of care.
  • Foundation Medicine® and FoundationOne® are registered trademarks of Foundation Medicine, Inc.

SciSparc Granted Patent for its Core Technology From the Australian Patent Office

Retrieved on: 
Tuesday, October 24, 2023
Combination, Patent, TEL, Legislation, IP Australia, N-Acylethanolamine, Disorder, Safety, Collection, Central nervous system, Pharmaceutical industry, Cannabinoid

TEL AVIV, Israel, Oct. 24, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that it received a notice of acceptance for its patent application for the Combinations of Cannabinoids and N-Acylethanolamines (the “Patent”). The Patent aligns seamlessly with the Company's core technologies design to enhance cannabinoids’ safety by using low dosages of active components while maintaining their therapeutic benefits.

Key Points: 
  • The Patent aligns seamlessly with the Company's core technologies design to enhance cannabinoids’ safety by using low dosages of active components while maintaining their therapeutic benefits.
  • The Patent was granted by IP Australia, the government agency in Australia that administers intellectual property rights and legislation for patents.
  • This Patent adds to the collection of patents previously granted in Europe, the United States and Japan, supporting the innovation of SciSparc’s technologies.
  • The invention relates to compositions and methods for potentiating therapeutic effects and/or reducing the side-effects of selected cannabinoids initially discovered in the cannabis plant.

DevvStream Reaches Key Milestone Toward Nasdaq Listing

Retrieved on: 
Tuesday, October 24, 2023
Combination, Register, Public Company Accounting Oversight Board, Security (finance), Business analyst, Form, Carbon, Transaction, Bank statement, Registration statement, FIAC, CBOE, FSE, DESG, Culture

The Transaction values DevvStream at an implied enterprise value of approximately $212.8 million, representing an equity value of C$2.16 per DevvStream subordinate voting share prior to closing.

Key Points: 
  • The Transaction values DevvStream at an implied enterprise value of approximately $212.8 million, representing an equity value of C$2.16 per DevvStream subordinate voting share prior to closing.
  • The Business Combination is expected to be completed by early Q1 2024, subject to the satisfaction of closing conditions under the Business Combination Agreement.
  • Learn more about the Company’s progress by joining a live webinar presented by DevvStream and Focus Impact on Thursday, October 26th at 9:30am PT / 12:30pm ET.
  • “Since DevvStream and Focus Impact agreed to merge, the transaction has proceeded smoothly and efficiently,” said Sunny Trinh, CEO of DevvStream.

Vision Sensing Acquisition Corp. Announces Postponement of Special Meeting of Stockholders to Wednesday, October 25, 2023 at 12:00 noon EDT

Retrieved on: 
Thursday, October 19, 2023
Transfer, Combination, Business analyst, EDT, VSAC, EST, Intellectual property, Acquisition, Research, Trust Company, Trust, Companies (1st Amendment) Act, 2015, Special, Sub, Extension, Continental, Security (finance)

NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “Company”) a special purpose acquisition company, announced today that it has postponed the Special Meeting of its Stockholders scheduled to occur at 8:30 a.m. EDT on Friday, October 20, 2023 until 12:00 noon EDT on Wednesday, October 25, 2023.

Key Points: 
  • NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “Company”) a special purpose acquisition company, announced today that it has postponed the Special Meeting of its Stockholders scheduled to occur at 8:30 a.m. EDT on Friday, October 20, 2023 until 12:00 noon EDT on Wednesday, October 25, 2023.
  • 1 dated May 1, 2023 with Continental Stock Transfer and Trust Company (“Continental”).
  • Adoption of the Extension Amendment entitles VSAC’s public stockholders to require the redemption of their VSAC Class A common stock with funds from VSAC’s trust account.
  • Pursuant to the Business Combination Agreement, Merger Sub will merge with and into VSAC, with VSAC surviving the merger.

Renesas Develops Cost-Effective, Highly Accurate and Robust Induction Motor Position Sensing Technology

Retrieved on: 
Wednesday, October 25, 2023
Software, Other Manufacturing, Hardware, Engineering, Technology, Semiconductor, Manufacturing, Other Technology, Lightwave Electronics Corporation, Combination, Data analysis, Vibration, UART, Dust, ICS, Humidity, ABI, IPS, Sensor, Multimedia, EMI, Vernier, Renesas Electronics, PCB, Safety, Winning Combination, Robotics, Instrumentation

Renesas Electronics Corporation (TSE:6723), a premier supplier of advanced semiconductor solutions, today announced an inductive position sensor (IPS) technology for highly accurate motor position sensor ICs for robotics, industrial and medical applications.

Key Points: 
  • Renesas Electronics Corporation (TSE:6723), a premier supplier of advanced semiconductor solutions, today announced an inductive position sensor (IPS) technology for highly accurate motor position sensor ICs for robotics, industrial and medical applications.
  • Utilizing non-contact coil sensors, the position sensing technology can replace expensive magnetic and optical encoders now commonly used in motor control systems that require absolute position sensing, high speed, accuracy and reliability.
  • View the full release here: https://www.businesswire.com/news/home/20231025174265/en/
    The proprietary IPS technology from Renesas uses sensing elements consisting of copper coils etched on a printed circuit board (PCB) to detect the position of a metallic target.
  • “Our induction position sensor technology represents a significant leap forward in motor position sensors,” said Jan Leuckfeld, Senior Director, HPC Analog (Sensor) Division at Renesas.

Aeries Technology and Worldwide Webb Acquisition Corporation Announce Effectiveness of Registration Statement and October 30, 2023 Annual General Meeting to Approve Business Combination

Retrieved on: 
Tuesday, October 17, 2023
Software, Networks, Data Analytics, Finance, Consulting, Banking, Professional Services, Technology, WWAC, Combination, Business analyst, Annual general meeting, Form, Acquisition, Kirkland & Ellis, Annual, Security (finance)

The annual general meeting of shareholders (the “Annual General Meeting”) to approve the Business Combination is scheduled to be held on October 30, 2023 at 11:00 a.m. Eastern Time.

Key Points: 
  • The annual general meeting of shareholders (the “Annual General Meeting”) to approve the Business Combination is scheduled to be held on October 30, 2023 at 11:00 a.m. Eastern Time.
  • Holders of WWAC’s ordinary shares at the close of business on the record date of September 13, 2023 are entitled to notice of the Annual General Meeting and to vote at the Annual General Meeting.
  • More details about the Business Combination and the resolutions to be voted upon at the Annual General Meeting can be found in the definitive proxy statement/prospectus filed by WWAC, available at: http://www.sec.gov .
  • The Nasdaq listing is subject to the closing of the business Combination and fulfillment of all Nasdaq listing requirements.